Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.00408-2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination Inhaled Corticosteroid and Short-acting Beta2 Agonist (ICS-SABA) Use for Older Adults With Asthma.
Sr Care Pharm
January 2025
2 Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas.
The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used.
View Article and Find Full Text PDFGINA step 1-2 therapy: Low-dose ICSformoterol combination taken as needed or moderate-dose ICS-formoterol combination taken as needed?
Tuberk Toraks
December 2024
Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
As-Needed Inhaled Corticosteroid-Formoterol in a Single Inhaler Compared to Inhaled Corticosteroid-Albuterol in Separate Inhalers as Reliever Therapy in Mild Pediatric Asthma: A Cost-Utility Analysis.
Pediatr Pulmonol
December 2024
Department of Pharmacology and Toxicology, School of Medicine, Research Group in Pharmacology and Toxicology (INFARTO), Universidad de Antioquia, Medellín, Colombia.
Objectives: Since 2019 as-needed low-dose ICS-formoterol in a single inhaler has been recommended for treatment of mild asthma in children aged more than 12 years. Alternatively, the use of ICS-albuterol has been proposed in countries where ICS-formoterol is not available or affordable. The aim of the present study was to evaluate the cost-utility of as-needed ICS-albuterol in separate inhalers compared to ICS-formoterol in a single inhaler as reliever therapy in pediatric patients with mild asthma living in Colombia.
View Article and Find Full Text PDFUpdate on Asthma Management Guidelines.
Mo Med
October 2024
Pulmonary and Critical Care Fellow, Department of Pulmonary and Critical Care Medicine, University of Missouri-Kansas City, Kansas City, Missouri.
The Global Initiative for Asthma (GINA) was established in 1993 and publishes a yearly global strategy to improve asthma awareness, prevention and management of asthma worldwide, based on a review of the most updated evidence. The current 2024 GINA update advises that all adults and adolescents with asthma receive inhaled corticosteroid (ICS)- containing medication and should not be treated with short acting beta agonist (SABA) alone. The 2024 GINA strategy divides treatment into two 'Tracks": Track 1 (preferred Track), the reliever is as-needed combination low dose ICS-formoterol; Track 2 uses SABA as the reliever along with a separate ICS inhaler.
View Article and Find Full Text PDFShort-acting β-agonists (SABA) overuse in asthma and patients' perceptions for this behavior.
Respir Med
September 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Royal Dutch Pharmacists Association (KNMP), The Hague, the Netherlands.
Background: Short-acting β-agonists (SABA) overuse is associated with poor asthma control. The Global Initiative for Asthma (GINA) 2019-updated strategy report has therefore taken a paradigm shift in reliever therapy recommendations.
Objectives: (I) To investigate the status of SABA overuse and medication dispensing patters in asthma in the Netherlands (II) validate dispensing data for SABA overuse identification and (III) understand patients' perspectives towards this SABA-taking behavior to inform future improvement strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!